Decoy Therapeutics Inc (DCOY) FinancialsDCOYDecoy Therapeutics Inc

Evaluating the bottom line, Decoy Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1055.84%, while the net margin is -1042.84%. These profitability ratios, combined with a Return on Equity (ROE) of -827.77%, provide a clear picture of how effectively DCOY converts its operational activities into shareholder value.

In the context of the broader market, DCOY competes directly with industry leaders such as REVB and CLDI. With a market capitalization of $2.70M, it holds a leading position in the sector. When comparing efficiency, DCOY's gross margin of 100.00% stands against REVB's N/A and CLDI's N/A. Such benchmarking helps identify whether Decoy Therapeutics Inc is trading at a premium or discount relative to its financial performance.

DCOY has reported zero revenue for multiple quarters, with a recent gross margin of 100% in Q2 2026, but it continues to incur significant losses, including a net loss of $2,373,800.